Purdue Fends Off Generic OxyContin Competition

Law360, New York (August 29, 2006, 12:00 AM EDT) -- Purdue Pharma LP has settled separately two patent infringement suits over generic versions of its painkiller OxyContin, stipulating that the generic makers must stop producing their generics if the settlements receive antitrust approval.

Endo Pharmaceuticals has agreed to end its patent infringement lawsuit with Purdue, which has raged from the Southern District of New York to the Federal Circuit and back. The suit nearly cost Purdue its OxyContin patent.

Endo has agreed to stop selling its generic by the end of 2006, and in exchange, Purdue...
To view the full article, register now.